Recurrent erythema multiforme with oralinvolvement is therapeutically challenging.Apremilast has been used with success in resolvingthe oral aphthae of Behçet disease, prompting theuse of the drug in patients with oral erosions fromerythema multiforme. Three patients with oralerythema multiforme were given apremilast at dosesof 30-60mg daily. Complete clearance of the lesionswere observed in all three patients, including thoserefractory to other standard therapies. Apremilast maypresent an effective option for recurrent erythemamultiforme for patients who have failed trials antiviraland immunosuppressive therapies.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jhKOgk
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
We are excited to share with you the newest dentistry and patient safety editions recently added to STAT!Ref. As a reminder, all STAT!Ref c...
-
Abstract Sexual dimorphism in the human respiratory system has been previously reported at the skeletal (cranial and thoracic) level, but ...
-
Abstract The effects of oxygen addition on a helium-based flowing atmospheric pressure afterglow (FAPA) ionization source are explored. Sm...
-
Objective Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. Ho...
-
2016-12-10T02-17-59Z Source: Indo American Journal of Pharmaceutical Research M.R. Pradeep Kumar*, Shrinivas D. Joshi . With an objecti...
-
Related Articles Corrections. Otolaryngol Head Neck Surg. 2007 Dec;137(6):987 Authors: PMID: 29135374 [PubMed] from #AlexandrosS...
-
http://ift.tt/2svTdo9
-
The evaluation of mineral resources development efficiency is a typical multicriteria decision-making issue. Meanwhile, due to the limited e...
-
Photochem. Photobiol. Sci. , 2018, Accepted Manuscript DOI : 10.1039/C7PP00350A, Paper Yan Xie, Jianrong Gao, Shaozheng Zhang, Liang Wu F...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου